What Are the ICD-10 Codes for Immunosuppressive Therapy?
There is not one universal ICD-10-CM code for every immunosuppressive therapy encounter. The appropriate code depends on what is being documented.
For long-term medication use, the Z79.62- family identifies long-term current use of immunosuppressants, with additional specificity for the type of therapy. The FY2026 code set includes codes for immunosuppressive biologics, calcineurin inhibitors, Janus kinase inhibitors, mTOR inhibitors, and inhibitors of nucleotide synthesis.
The underlying condition should generally remain part of the coding picture when it is documented and relevant to the encounter. A medication-use code does not automatically replace the disease being treated.
Major immunosuppressive therapy codes
| Condition or scenario | ICD-10-CM code | Description |
|---|---|---|
| Long-term immunosuppressive therapy, unspecified | Z79.60 | Long term (current) use of unspecified immunomodulators and immunosuppressants |
| Long-term immunomodulator use | Z79.61 | Long term (current) use of immunomodulator |
| Immunosuppressive biologic | Z79.620 | Long term (current) use of immunosuppressive biologic |
| Calcineurin inhibitor | Z79.621 | Long term (current) use of calcineurin inhibitor |
| Janus kinase inhibitor | Z79.622 | Long term (current) use of Janus kinase inhibitor |
| mTOR inhibitor | Z79.623 | Long term (current) use of mammalian target of rapamycin inhibitor |
| Nucleotide synthesis inhibitor | Z79.624 | Long term (current) use of inhibitors of nucleotide synthesis |
| Other immunomodulators/immunosuppressants | Z79.69 | Long term (current) use of other immunomodulators and immunosuppressants |
| Long-term systemic steroid use | Z79.52 | Long term (current) use of systemic steroids |
| Personal history of immunosuppression therapy | Z92.25 | Personal history of immunosuppression therapy |
The exact code should be supported by the medication and provider documentation. For example, Z79.621 should not be selected simply because a patient is receiving “immunosuppressive therapy”; the record must support current long-term use of a calcineurin inhibitor.
CMS’s FY2026 code definitions confirm the detailed Z79.62- and related categories.
Which ICD-10-CM Version Applies?
If your encounters fall within April 1, 2026 – September 30, 2026, use the April 1, 2026 FY2026 ICD-10-CM release, which is identified as the official FY2026 ICD-10-CM codeset for Encounters occurring in this time period by the CDC and CMS.
ICD-10-CM is date-sensitive, so verify the ICD-10-CM version for date of service to avoid outdated, archived, or in-encoder coding information.
You can utilize the CDC ICD-10-CM browser to view Alphabetical Index, Tabular List, Instructional Notes and specific FY year data.
How to Select the Correct Immunosuppressive Therapy Code
1. Start with the provider’s documented diagnosis
First determine why the patient is receiving therapy.
Examples may include:
- Rheumatoid arthritis
- Crohn’s disease
- Ulcerative colitis
- Psoriasis or psoriatic disease
- Lupus
- Organ transplantation
- Other autoimmune or inflammatory disorders
- A documented condition requiring immunosuppression
Do not allow the medication name alone to establish a diagnosis that the provider has not documented.
2. Determine whether the medication is current and long term
The Z79 category is designed to identify long-term current drug therapy. It is not intended simply because a drug was administered once or used briefly for an acute condition.
The documentation should support the patient’s ongoing therapy when a long-term-use code is assigned.
3. Identify the specific type of immunosuppressant
If documentation identifies the drug class, select the most specific supported Z79.62- code rather than automatically using an unspecified category.
For example:
- Calcineurin inhibitor → Z79.621
- JAK inhibitor → Z79.622
- mTOR inhibitor → Z79.623
- Nucleotide synthesis inhibitor → Z79.624
- Immunosuppressive biologic → Z79.620
4. Capture the underlying disease
The medication-use code and disease code serve different purposes. If the patient is being treated for a documented autoimmune disease, transplant-related condition, inflammatory disorder, or another active condition, review the record for the appropriate disease-specific ICD-10-CM code.
Do not replace a documented disease diagnosis with Z79.62- merely because immunosuppressive medication is being used.
5. Check for adverse effects and complications
A different coding approach may apply when the encounter is specifically for an adverse effect or complication of an immunosuppressive drug.
For example, T45.1X5- is used for adverse effects of antineoplastic and immunosuppressive drugs when applicable. The final character depends on the encounter circumstances.
The FY2026 Official Guidelines provide examples showing that when treatment is directed at an adverse-effect-related condition, sequencing can differ from a routine therapy encounter.
CPT Codes for Immunosuppressive Therapy Administration
ICD-10-CM codes identify diagnoses and relevant patient circumstances. CPT and HCPCS codes describe the services and drugs being billed. Therefore, an immunosuppressive therapy claim may require both diagnosis coding and procedure/drug coding.
The correct CPT administration code depends on the drug, route, complexity, and manner of administration.
Common administration code families include:
| Service | Common CPT range/code | Billing consideration |
| Therapeutic/diagnostic IV infusion of non-chemotherapy drugs | 96365-96368 | Selection depends on initial, additional-hour, sequential, or concurrent circumstances |
| Therapeutic/diagnostic IV push | 96374-96376 | Depends on initial, additional, sequential, or repeat administration |
| Subcutaneous/intramuscular therapeutic injection | 96372 | Used for qualifying therapeutic injections |
| Chemotherapy/highly complex drug or biologic administration | 96401-96549 | Applicability depends on the drug and administration circumstances |
| Initial IV infusion for chemotherapy/highly complex drug | 96413 | Appropriate only when the service meets the CPT definition |
| Additional hour of chemotherapy infusion | 96415 | Time-based add-on service |
| Additional sequential chemotherapy infusion | 96417 | Used for qualifying sequential infusions |
| Additional chemotherapy IV push | 96411 | Additional drug/substance in qualifying circumstances |
| Port/catheter declotting | 36593 | Used when the service meets the code definition |
CMS’s NCCI guidance distinguishes non-chemotherapy therapeutic/diagnostic administration codes 96360-96379 from chemotherapy or highly complex drug/biologic administration codes 96401-96549.
Important: Do not select a CPT code solely because the medication is an immunosuppressant. The drug’s classification and the actual administration service determine the appropriate CPT/HCPCS reporting.
Immunosuppressive Therapy Billing: Diagnosis, Drug and Administration
A clean claim may involve three separate coding components:
- Diagnosis code — explains the patient’s condition or relevant treatment status.
- Administration CPT code — reports how the medication was administered.
- Drug HCPCS code — reports the specific drug when separately billable and applicable.
For example, a patient with a documented autoimmune condition receives a qualifying biologic infusion. The claim may require the disease diagnosis, an appropriate drug code, and the correct infusion administration code based on the service performed.
The exact combination depends on the drug, payer, setting, medical necessity requirements, and documentation.
CMS guidance also emphasizes that the submitted ICD-10-CM diagnosis must support the service and that the CPT/HCPCS code must accurately describe the service or drug provided.
High-Risk Immunosuppressive Therapy Coding Scenarios
Long-term therapy versus a single administration
A patient receiving an ongoing immunosuppressant may qualify for a Z79.62- code when the documentation supports long-term current use. A one-time medication administration should not automatically be reported as long-term therapy.
Immunosuppressive therapy after transplantation
Transplant patients often have several relevant coding elements. The transplant status, underlying condition, current therapy, and reason for the encounter should be reviewed independently.
Do not assume that one Z-code captures the entire clinical picture.
Drug-related adverse effects
When a documented condition results from an adverse effect of an immunosuppressive drug, the coding sequence may require the adverse-effect code in addition to the condition being treated.
For example, if an encounter is specifically for management of anemia associated with an adverse effect of immunotherapy, the FY2026 Official Guidelines provide sequencing direction for the anemia, neoplasm, and adverse effect codes as applicable.
Steroid therapy
Systemic steroid use should not automatically be placed under the immunosuppressant-specific Z79.62- category. FY2026 includes separate long-term-use codes for systemic steroids, including Z79.52.
Documentation Checklist for Providers
Strong documentation makes both coding and billing easier. The medical record should clearly support:
| Documentation item | Why it matters |
| Confirmed diagnosis | Establishes the condition being treated |
| Reason for immunosuppressive therapy | Supports medical necessity |
| Medication name | Identifies the therapy |
| Drug class when relevant | Supports specific long-term-use coding |
| Current/long-term status | Helps determine whether Z79 coding applies |
| Route of administration | Supports CPT administration selection |
| Dose and units | Supports drug billing |
| Start and stop times for applicable infusions | Supports time-based administration services |
| Adverse effect or complication, when present | May change diagnosis coding and sequencing |
| Transplant status, when relevant | Supports complete clinical coding |
| Provider assessment and plan | Establishes the documented relationship between treatment and condition |
Weak documentation
Patient on immunosuppressants.
This does not identify the medication, reason for therapy, or whether the therapy is current and long term.
Better documentation
Patient continues tacrolimus therapy following kidney transplantation.
This gives the coding team substantially more information about the treatment and clinical context.
Stronger documentation
“Patient remains on long-term tacrolimus immunosuppression following kidney transplantation; therapy continued today with monitoring for medication-related complications.”
The final code selection must still be based on the complete record and applicable coding instructions.
Practical Coding Examples
| Clinical documentation | Coding approach | Main billing lesson |
| Patient is on long-term immunosuppressive biologic therapy | Consider Z79.620 when supported | Identify the specific therapy category |
| Patient uses a calcineurin inhibitor long term | Consider Z79.621 | Drug class matters |
| Patient uses a JAK inhibitor long term | Consider Z79.622 | Do not default to unspecified therapy |
| Patient uses an mTOR inhibitor long term | Consider Z79.623 | Verify the medication class |
| Patient uses an inhibitor of nucleotide synthesis long term | Consider Z79.624 | Match documentation to the code category |
| Patient receives systemic steroids long term | Review Z79.52 | Steroids have separate Z79 coding |
| Encounter is for a documented drug adverse effect | Review applicable T36-T50 adverse-effect coding | Sequencing depends on the reason for the encounter |
| Patient has an active autoimmune disease and uses immunosuppressive medication | Code the documented disease plus applicable therapy/status code when supported | Do not substitute medication status for the disease |
These examples illustrate coding logic rather than universal claim combinations. Final reporting depends on the patient’s documentation and applicable coding instructions.
Infusion Billing Mistakes That Cause Problems
Reporting multiple initial infusion codes
CMS NCCI guidance states that only one initial service code is generally reported for an encounter unless separate initial services through separate IV access sites are medically reasonable and necessary.
Ignoring administration time
For time-based infusion services, the record should support actual administration time. CMS guidance emphasizes documenting start and stop times or total administration time when applicable.
Separately billing incidental hydration
Hydration associated with drug administration may not always be separately reportable. The circumstances of the service and applicable CPT/NCCI guidance must be reviewed before adding a hydration code.
Choosing an administration code from the drug name alone
The same broad therapy category can involve different routes and administration methods. CPT selection must follow the actual service performed.
Using an unspecified diagnosis when documentation supports specificity
If the provider documents the specific medication class, disease, complication, or treatment relationship, the coding team should review whether a more specific code is available.
Best Practices for Clean Immunosuppressive Therapy Claims
Connect the diagnosis to medical necessity
The diagnosis reported on the claim should support why the medication, infusion, injection, monitoring, or related service was medically necessary.
Separate disease coding from therapy-status coding
Think of these as two different questions:
What condition does the patient have?
and
What long-term therapy is the patient currently receiving?
Answering both questions correctly can produce a more complete claim.
Build EHR documentation prompts
Specialty practices can create documentation prompts asking clinicians to identify the medication, indication, therapy status, route, and relevant complications.
Audit unspecified-code utilization
A high volume of unspecified Z79.6/Z79.69-type coding may indicate that medication-class information is not reaching the coding team. Reviewing these cases can identify documentation improvement opportunities.
Use provider queries appropriately
When the record contains conflicting or incomplete information, a compliant provider query may be appropriate. Coders should not independently establish a diagnosis or drug-related causal relationship that the provider has not documented.
Final Claim Verification Checklist
Before submitting an immunosuppressive therapy claim, verify:
Conclusion
Accurate Immunosuppressive Therapy ICD-10 Codes depend on more than identifying that a patient receives immunosuppressive medication. Coding teams should evaluate the underlying disease, current treatment status, specific medication class, complications, adverse effects, administration method, and applicable sequencing instructions.
For billing purposes, ICD-10-CM diagnosis coding must also align with the CPT or HCPCS services reported. Administration codes such as 96365-96379 and 96401-96549 have different requirements, so the actual drug and service—not simply the phrase “immunosuppressive therapy”—should drive CPT selection.
Using specific provider documentation, current date-of-service code sets, appropriate diagnosis and therapy-status codes, and payer-specific medical-necessity requirements can help healthcare organizations reduce avoidable denials, improve claim accuracy, and strengthen audit defensibility.
Frequently Asked Questions
What is the ICD-10 code for immunosuppressive therapy?
There is no single code for every immunosuppressive therapy encounter. For long-term current use, the Z79.62- family provides specific codes for immunosuppressive biologics, calcineurin inhibitors, JAK inhibitors, mTOR inhibitors, and nucleotide synthesis inhibitors.
What is Z79.620 used for?
Z79.620 identifies long-term current use of an immunosuppressive biologic. The medication and documentation must support that classification.
What is Z79.621 used for?
Z79.621 identifies long-term current use of a calcineurin inhibitor. It should be assigned only when the documented therapy supports the code.
What is Z79.622?
Z79.622 represents long-term current use of a Janus kinase inhibitor. The medication documented in the record should support this classification.
Is Z79.52 an immunosuppressive therapy code?
Z79.52 identifies long-term current use of systemic steroids. Steroid therapy has its own Z79 category and should not automatically be reported as Z79.62-.
Can an immunosuppressive therapy code be billed alone?
Not necessarily. A therapy-status code generally does not replace the diagnosis responsible for treatment. Review the complete encounter and payer requirements to determine the appropriate diagnosis coding.
What CPT code is used for immunosuppressive infusions?
There is no single CPT code for every immunosuppressive infusion. Depending on the drug and service, administration may fall under therapeutic/non-chemotherapy infusion codes such as 96365 or chemotherapy/highly complex drug or biologic administration codes such as 96413. The actual drug and administration circumstances must be reviewed.
Can coders determine immunosuppressive therapy from the medication alone?
The medication can help identify the appropriate therapy category, but coders should rely on provider documentation and the official code-set instructions rather than independently diagnosing a condition or inferring an undocumented causal relationship.
Does correct ICD-10 coding guarantee payment?
No. Correct diagnosis coding is essential, but payment can also depend on medical necessity, CPT/HCPCS reporting, payer coverage, authorization, documentation, modifier requirements, benefit limitations, and other claim requirements.
When should a provider query be considered?
A query may be appropriate when documentation is incomplete, conflicting, or unclear and clarification could materially affect accurate coding. The query should seek clarification without leading the provider toward a predetermined diagnosis or code.